FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020365513> ?p ?o ?g. }

• W2020365513 endingPage "P225" @default.
• W2020365513 startingPage "P225" @default.
• W2020365513 abstract "7-11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK Lersivirine (LRV) is a next-generation NNRTI currently under investigation in two Phase IIb studies at doses of 500 - 1000 mg QD. In vitro analyses suggest that LRV is a weak Ikr and CA2+ channel blocker. However, dose-ranging Phase I studies have not shown prolongation of QTc interval to date. This study was performed to investigate the effect of a supratherapeutic dose of LRV on QTc interval in healthy subjects, relative to matched placebo and active control. A randomized, single-dose, placebo- and active-controlled 3-way crossover study was performed with 48 healthy adults. Subjects were randomized to receive either LRV (2400 mg), moxifloxacin (400 mg) or placebo for each treatment period with minimum washout of 7 days. Triplicate 12-lead electrocardiogram (ECG) measurements were performed and PK samples collected predose and at 1, 2, 3, 4, 5, 6, 9, 12, and 24 hrs postdose. Vital signs were measured predose, 3 hrs postdose and at discharge. Adverse event monitoring and safety laboratory testing were performed throughout. All 48 subjects enrolled were white males (mean age 39.1 yrs, body mass index 25.6 kg/m2) and completed the study. Following LRV administration, the upper bound of 90% CI for time-matched adjusted mean differences to placebo in QTcF at each of the time points postdose was below the regulatory threshold of 10 msec, thus satisfying the criteria for a negative thorough QT/QTc study. The highest upper bound of 90% CI occurred at 6 hrs for LRV (3.32, 90% CI 1.5, 5.1). The study was deemed adequately sensitive as the lower bound of the 90% CI for the adjusted mean differences between moxifloxacin and placebo at moxifloxacin's historical Tmax of 3 hrs was >5 msec (15.29 msec, 90% CI: 13.5, 17.1 msec). No subjects receiving LRV or placebo had a QTcF ≥450 msec, nor did any experience a QTcF increase ≥30 msec from baseline at any time point. In subjects receiving LRV, no clinically significant changes in QRS complex, PR interval, heart rate or blood pressure were observed. PK analysis of blood samples indicated geometric mean (CV%) AUClast 17750 ng.hr/mL (28%) and Cmax 1727 ng/mL (33%), and median Tmax 3 hrs. Adverse events were generally mild, with some moderate gastrointestinal events. LRV administered as a single 2400 mg supratherapeutic dose did not prolong the QTc interval and no clinically relevant ECG or vital sign changes were observed in healthy subjects." @default.
• W2020365513 created "2016-06-24" @default.
• W2020365513 creator A5022458571 @default.
• W2020365513 creator A5023907922 @default.
• W2020365513 creator A5074358267 @default.
• W2020365513 creator A5080798512 @default.
• W2020365513 creator A5082102963 @default.
• W2020365513 date "2010-11-01" @default.
• W2020365513 modified "2023-09-27" @default.
• W2020365513 title "No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects" @default.
• W2020365513 doi "https://doi.org/10.1186/1758-2652-13-s4-p225" @default.
• W2020365513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3113011" @default.
• W2020365513 hasPublicationYear "2010" @default.
• W2020365513 type Work @default.
• W2020365513 sameAs 2020365513 @default.
• W2020365513 citedByCount "0" @default.
• W2020365513 crossrefType "journal-article" @default.
• W2020365513 hasAuthorship W2020365513A5022458571 @default.
• W2020365513 hasAuthorship W2020365513A5023907922 @default.
• W2020365513 hasAuthorship W2020365513A5074358267 @default.
• W2020365513 hasAuthorship W2020365513A5080798512 @default.
• W2020365513 hasAuthorship W2020365513A5082102963 @default.
• W2020365513 hasBestOaLocation W20203655131 @default.
• W2020365513 hasConcept C118441451 @default.
• W2020365513 hasConcept C126322002 @default.
• W2020365513 hasConcept C142724271 @default.
• W2020365513 hasConcept C168563851 @default.
• W2020365513 hasConcept C197934379 @default.
• W2020365513 hasConcept C204787440 @default.
• W2020365513 hasConcept C27081682 @default.
• W2020365513 hasConcept C2778836808 @default.
• W2020365513 hasConcept C42219234 @default.
• W2020365513 hasConcept C44249647 @default.
• W2020365513 hasConcept C501593827 @default.
• W2020365513 hasConcept C71924100 @default.
• W2020365513 hasConcept C86803240 @default.
• W2020365513 hasConcept C87813604 @default.
• W2020365513 hasConcept C89423630 @default.
• W2020365513 hasConcept C98274493 @default.
• W2020365513 hasConceptScore W2020365513C118441451 @default.
• W2020365513 hasConceptScore W2020365513C126322002 @default.
• W2020365513 hasConceptScore W2020365513C142724271 @default.
• W2020365513 hasConceptScore W2020365513C168563851 @default.
• W2020365513 hasConceptScore W2020365513C197934379 @default.
• W2020365513 hasConceptScore W2020365513C204787440 @default.
• W2020365513 hasConceptScore W2020365513C27081682 @default.
• W2020365513 hasConceptScore W2020365513C2778836808 @default.
• W2020365513 hasConceptScore W2020365513C42219234 @default.
• W2020365513 hasConceptScore W2020365513C44249647 @default.
• W2020365513 hasConceptScore W2020365513C501593827 @default.
• W2020365513 hasConceptScore W2020365513C71924100 @default.
• W2020365513 hasConceptScore W2020365513C86803240 @default.
• W2020365513 hasConceptScore W2020365513C87813604 @default.
• W2020365513 hasConceptScore W2020365513C89423630 @default.
• W2020365513 hasConceptScore W2020365513C98274493 @default.
• W2020365513 hasLocation W20203655131 @default.
• W2020365513 hasLocation W20203655132 @default.
• W2020365513 hasLocation W20203655133 @default.
• W2020365513 hasOpenAccess W2020365513 @default.
• W2020365513 hasPrimaryLocation W20203655131 @default.
• W2020365513 hasRelatedWork W1524573729 @default.
• W2020365513 hasRelatedWork W1604467628 @default.
• W2020365513 hasRelatedWork W2038316072 @default.
• W2020365513 hasRelatedWork W2059530273 @default.
• W2020365513 hasRelatedWork W2087694690 @default.
• W2020365513 hasRelatedWork W2089254981 @default.
• W2020365513 hasRelatedWork W2094255619 @default.
• W2020365513 hasRelatedWork W2130165766 @default.
• W2020365513 hasRelatedWork W2332733266 @default.
• W2020365513 hasRelatedWork W2591541276 @default.
• W2020365513 hasVolume "13" @default.
• W2020365513 isParatext "false" @default.
• W2020365513 isRetracted "false" @default.
• W2020365513 magId "2020365513" @default.
• W2020365513 workType "article" @default.